2013
DOI: 10.1016/j.brainres.2013.07.001
|View full text |Cite
|
Sign up to set email alerts
|

The spatio-temporal expression of MHC class I molecules during human hippocampal formation development

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
25
0
2

Year Published

2014
2014
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 26 publications
(28 citation statements)
references
References 53 publications
1
25
0
2
Order By: Relevance
“…Slides were stained with the monoclonal antibody HC-10, which recognizes b2m-free HLA-A3, -A10, -A28, -A29, -A30, -A31, -A32, -A33, and -B (excluding HLA-B5702, -5804, and -B73), the monoclonal antibody HCA-2 specific for b2m-free HLA-A (except HLA-A24), -B7301, and -G heavy chains, EP1395Y antibody (Abcam; 1:250, pretreatment with Tris buffer at 100 for 20 minutes), and the monoclonal antibody EMR8-5 (Abcam; 1:4000, pretreatment with citrate at 100 for 30 minutes) specific for heavy chains of human HLA class 1 A, -B, and -C as previously described. [20][21][22][23][24][25] Staining and expression patterns for all 4 tested antibodies were compared on a case-by-case basis by 3 independent observes (E.A., G.M., and V.H.K.) and found to be consistent ( Fig S2).…”
Section: Methodsmentioning
confidence: 99%
“…Slides were stained with the monoclonal antibody HC-10, which recognizes b2m-free HLA-A3, -A10, -A28, -A29, -A30, -A31, -A32, -A33, and -B (excluding HLA-B5702, -5804, and -B73), the monoclonal antibody HCA-2 specific for b2m-free HLA-A (except HLA-A24), -B7301, and -G heavy chains, EP1395Y antibody (Abcam; 1:250, pretreatment with Tris buffer at 100 for 20 minutes), and the monoclonal antibody EMR8-5 (Abcam; 1:4000, pretreatment with citrate at 100 for 30 minutes) specific for heavy chains of human HLA class 1 A, -B, and -C as previously described. [20][21][22][23][24][25] Staining and expression patterns for all 4 tested antibodies were compared on a case-by-case basis by 3 independent observes (E.A., G.M., and V.H.K.) and found to be consistent ( Fig S2).…”
Section: Methodsmentioning
confidence: 99%
“…Neuronal expression of MHC-I in the human brain has only been reported in a small number of studies. The first was a study of a childhood viral infection, Rasmussen’s encephalitis, in which immunolabel for the MHC-I component, beta 2 microglobulin (β2m), was present in cortical and hippocampal neurons 20 ; more recently, MHC-I has also been observed in dysmorphic/dysphasic cortical neurons of focal cortical dysplasia, tuberous sclerosis complex and ganglioglioma cases 21 and in the embryonic LGN of the dorsal thalamus 22 and hippocampus 23 . In the LGN, β2m was observed at 29–31 gestational weeks but, was nearly absent by postnatal day 55, and was completely absent in the adult 22 .…”
Section: Introductionmentioning
confidence: 99%
“…We have proposed that this mechanism underlies the injury of demyelinated axons in multiple sclerosis (MS) 1, 2, 4, 10. Evidence also suggests that MHC I is involved with synaptic pruning during cortical development12, 13, 14, 16, 17, 18, 19, 20, 21 and following injury22, 23, 24, 25 and contributes to neuronal plasticity 16, 17, 26, 27. These findings also suggest that retrogradely induced MHC class I may contribute to the diffuse synaptopathy observed in MS and other neurodegenerative diseases 28, 29, 30, 31, 32, 33, 34, 35.…”
Section: Introductionmentioning
confidence: 99%